Antibiotic Treatment for Pneumonia Complicating Stroke: Recommendations From The Pneumonia in Stroke Consensus (PISCES) Group

Amit K Kishore\textsuperscript{1,2} MRCP, Adam R Jeans\textsuperscript{3} MD, Javier Garau\textsuperscript{4} PhD, Alejandro Bustamante\textsuperscript{5} PhD, Lalit Kalra\textsuperscript{6} PhD, Peter Langhorne\textsuperscript{7} PhD, Angel Chamorro\textsuperscript{8} PhD, Xabier Urra\textsuperscript{8} PhD, Mira Katan\textsuperscript{9} MD MSc, Mario Di Napoli\textsuperscript{10} MD, Willeke Westendorp\textsuperscript{11} MD, Paul J Nederkoorn\textsuperscript{11} PhD, Diederik van de Beek\textsuperscript{11} PhD, Christine Roffe\textsuperscript{12} MD, Mark Woodhead\textsuperscript{13} DM, Joan Montaner\textsuperscript{5,14} PhD, Andreas Meisel\textsuperscript{15} MD, Craig J Smith\textsuperscript{1,2} MD

\begin{itemize}
\item \textsuperscript{1}Greater Manchester Comprehensive Stroke Centre, Manchester Academic Health Science Centre, Salford Royal Foundation Trust, UK
\item \textsuperscript{2}Division of Cardiovascular Sciences, University of Manchester, Manchester, UK
\item \textsuperscript{3}Centre for Biostatistics, University of Manchester, Salford Royal Foundation Trust, UK
\item \textsuperscript{4}Department of Medicine, Hospital Universitari Mutua de Terrassa, Barcelona, Clinica Rotger Quironsalud, Palma of Mallorca, Spain
\item \textsuperscript{5}Neurovascular Research Lab, Vall d'Hebron Research Institute, Barcelona, Spain, Spain
\item \textsuperscript{6}Clinical Neurosciences, King's College Hospital NHS Foundation Trust London, UK
\item \textsuperscript{7}Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
\item \textsuperscript{8}Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain
\item \textsuperscript{9}Department of Neurology, Stroke Center, University Hospital of Zurich, Zurich, Switzerland
\item \textsuperscript{10}Stroke Unit, San Camillo de’ Lellis General Hospital, Rieti, Italy
\end{itemize}
Cover title: Antibiotic treatment for pneumonia complicating stroke

Corresponding author: Dr Amit K Kishore
Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Stott lane, Salford, M6 8HD, UK;
Tel: +44 161 206 4044 Fax: +44 161 707 6534 Amit.Kishore@manchester.ac.uk

Key Words: Stroke; Stroke-associated pneumonia; Post-stroke pneumonia; Antibiotics; Treatment

11 Amsterdam UMC, University of Amsterdam, Department of Neurology, Amsterdam Neuroscience, Meibergdreef, Amsterdam, Netherlands
12 Keele University Institute for Science and Technology in Medicine, Guy Hilton Research Centre, Stoke-on-Trent, UK
13 Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
14 Institute de Biomedicine of Seville, IBiS/Hospitales Universitarios Virgen del Rocío y Macarena, University of Seville, Seville, Spain
15 NeuroCure Clinical Research Center, Center for Stroke Research Berlin, Department of Neurology, Charité Universitätsmedizin Berlin, Germany
Abstract

**Purpose** - The microbiological etiology of pneumonia complicating stroke is poorly characterized. In this second Pneumonia In Stroke ConsEnsuS (PISCES-2) statement, we propose a standardized approach to empirical antibiotic therapy in pneumonia complicating stroke, based on likely microbiological etiology, to improve antibiotic stewardship.

**Methods** - Systematic literature searches of multiple databases were undertaken. An evidence review and a round of consensus consultation was completed prior to a final multidisciplinary consensus meeting in September 2017, held in Barcelona, Spain. Consensus was approached using a modified Delphi technique and defined a priori as 75% agreement between the consensus group members.

**Findings** - No randomized trials to guide antibiotic treatment of pneumonia complicating stroke were identified. Consensus was reached for the following: (1) Stroke-associated pneumonia (SAP) may be caused by organisms associated with either community-acquired or hospital-acquired pneumonia (CAP or HAP); (2) Treatment for early SAP (<72 h of stroke onset) should cover CAP organisms; (3) Treatment for late SAP (≥72 h and within 7 d of stroke onset) should cover CAP organisms plus coliforms +/- *Pseudomonas spp.* if risk factors; (4) No additional antimicrobial cover is required for patients with dysphagia or aspiration; (5) Pneumonia occurring after 7 d from stroke onset should be treated as for HAP; (6) Treatment should continue for at least 7 d for each of these scenarios.

**Discussion** - Consensus recommendations for antibiotic treatment of the spectrum of pneumonia complicating stroke are proposed. However there was limited evidence available to formulate consensus on choice of specific antibiotic class for pneumonia complicating stroke.

**Conclusion** - Further studies are required to inform evidence-based treatment of SAP including randomized trials of antibiotics and validation of candidate biomarkers.
Introduction

Pneumonia is a serious and common complication of stroke which is associated with significantly increased healthcare costs, poor functional outcome and mortality. The Pneumonia In Stroke ConsEnSuS (PISCES) group was formed as a multi-disciplinary initiative to address uncertainties in the diagnosis, prevention and treatment of pneumonia complicating stroke, and to identify key research priorities. The first PISCES consensus focused on terminology and diagnostic criteria for the spectrum of lower-respiratory tract infections, including the proposed definition and operational criteria for stroke-associated pneumonia (SAP).

In clinical practice, immediate treatment of pneumonia complicating stroke is recommended once suspected or diagnosed. Initial choice of antibiotics are often broad spectrum, being either clinician dependent or guided by various international guidelines for community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) or aspiration pneumonia. There is, however, substantial variation in antibiotic prescription practices across healthcare systems, which could have implications for clinical outcomes. Determining microbiological etiology in pneumonia complicating stroke is challenging given the difficulty in obtaining sputum samples in non-ventilated stroke patients and poor diagnostic sensitivity of other available culture specimens, which may limit definitive antibiotic treatment based on microbial sensitivities. Antibiotics commonly used to treat pneumonia complicating stroke vary in their spectrum of antimicrobial activity, and patterns of antibacterial resistance also vary around the globe, which are important considerations in empirical treatment. Transient immune suppression induced by acute stroke, involving both innate and adaptive responses, is a well-recognized phenomenon and might also impact on the effectiveness of antibiotics. Different antibiotic classes may also potentially influence outcomes by mechanisms
independent of their antimicrobial coverage, for example anti-inflammatory and immunomodulatory effects.\textsuperscript{11}

Choice of antibiotics for treatment of pneumonia complicating stroke may therefore have important implications for antibiotic stewardship and clinical outcomes in clinical practice. In this second PISCES group consensus process (PISCES-2) we aimed to formulate antibiotic treatment recommendations for pneumonia complicating stroke, and to identify areas for future research.
Methods

Membership of the PISCES Group and Protocol Development

The PISCES group was originally convened by the Chair (C.J.S) based on collective multidisciplinary expertise across the spectrum of SAP, pneumonia, respiratory medicine, stroke neurology, stroke unit and neurocritical care management, infectious diseases, clinical microbiology, systematic review, and clinical guidelines. For this consensus process the PISCES group included eighteen clinicians with representation from the UK, Germany, Spain, Italy, Netherlands and Switzerland. The protocol for the present study was drafted by the chair in conjunction with the co-chairs (A.M and J.M) and reviewed by the group to further define the objectives, methodology, and statements for consensus. The authors declare that all supporting data are available within the article [and its online supplementary files].

Systematic Literature Searches

An evidence review to inform the consensus development and process was undertaken as follows. As a first step, a systematic review and meta-analysis of microbiological etiologies implicated in pneumonia complicating stroke was undertaken and has been reported previously. A second systematic literature search sought to identify randomized controlled trials (RCTs) of antibiotic treatment for pneumonia complicating stroke (Table I in the online-only Data Supplement) in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Briefly, published studies of ischemic stroke, intracerebral hemorrhage (ICH), or both, involving antibiotic treatment of pneumonia were independently screened for eligibility (Table II in the online-only Data Supplement) by A.K.K and C.J.S using the study title and abstract. Online trials registries (ISRCTN Registry, ClinicalTrials.gov, ICTRP Portal) were also searched for registered ongoing or recently completed, unpublished RCTs. A summary of currently available antibiotic classes
in clinical practice, antimicrobial activities and antibiotic stewardship issues (including antibiotic resistance) was provided by the study microbiologist (A.R.J). Review of specialist societal recommendations for CAP, HAP and aspiration pneumonia was also undertaken, with reference to antibiotic classes used, led by A.K.K and the study infectious diseases specialist (J.G).

**Consensus Process**

A preliminary conference call formulated the remit, scope, themes and statements for consensus. Statements for consensus and an accompanying evidence review were circulated to the group by e-mail and a single round of provisional anonymized consensus and feedback was undertaken. The results were collated, presented and discussed at a final consensus group meeting along with summaries of antibiotic classes, sensitivities, resistance and societal recommendations for CAP, HAP and aspiration pneumonia in Barcelona, Spain on the 27th September 2017. *Consensus was approached using a modified Delphi technique (Hasson et al, 2000) and defined a priori as 75% agreement between the consensus group members.*

13
Findings

The main recommendations of the consensus process are summarized in Table 1 and Fig. 1. The consensus statements considered, including the online survey results and final consensus opinions are summarized in Table III in the online-only supplement.

Remit and Scope of the Consensus

The requirement for consensus-based guidelines for the empirical antibiotic treatment of pneumonia complicating stroke (ischemic stroke and ICH) was agreed by preliminary consensus. Agreement was also reached by preliminary consensus that the main focus of these recommendations should be SAP, defined in a previous publication as pneumonia within 7 days of stroke symptom onset including those receiving mechanical ventilation. Consensus was reached that beyond 7 days after stroke onset published societal guidelines for HAP should be applied. For the purpose of the present recommendations, a distinction was made between the well-documented phenomenon of stroke-induced transient immune suppression and that of pre-existing immune suppression (e.g. secondary to immune suppressant therapy) referred to in other societal guidelines of antibiotic treatment.

Recommendations

The guidelines apply mainly to Stroke-Associated Pneumonia (pneumonia ≤ 7d after stroke onset). Other specialist societal guidelines for HAP should be applied beyond 7 days after stroke onset.
Microbiological Etiology of SAP and Microbiological Testing

A systematic review of 15 studies of patients with pneumonia complicating stroke suggested that aerobic Gram negative bacilli (38%) and Gram positive cocci (16%) were most frequently isolated among positive cultures. Commonly isolated bacterial species included *Enterobacteriaceae* (21.8%: *Klebsiella pneumoniae*, 12.8% and *Escherichia coli*, 9%), *Staphylococcus aureus* (10.1%), *Pseudomonas aeruginosa* (6%), *Acinetobacter baumanii* (4.6%) and *Streptococcus pneumoniae* (3.5%). Reported frequency of positive culture data (15% to 88%) varied considerably between studies. Sputum was most commonly used to identify pathogens, in isolation (40%) or in conjunction with tracheal aspirate (15%) or blood culture (20%). Although the bacterial species identified appeared to be more closely related to HAP than ventilator-associated pneumonia (VAP) or hospitalized CAP, there were several limitations, including significant heterogeneity and inability to separate causal from commensal bacteria. There were insufficient data to identify the relative contributions of particular bacteria in relation to the timing of onset of SAP.

Anaerobes, often thought to be one of the primary bacterial groups causing aspiration pneumonia, were either not detected or reported in any of the studies. None of the studies in the review used modern molecular diagnostic techniques such as multiplex polymerase chain reaction (PCR) platforms to detect multiple bacterial species, respiratory viruses or atypical organisms. Difficulty in consistently obtaining sputum culture samples in non-ventilated stroke patients was acknowledged. Consensus was reached that bacterial species implicated in SAP may overlap with those associated with either CAP or HAP. It was acknowledged that evidence from other reviews on microbiological etiology for hospitalized CAP or HAP should also be considered when recommending antibiotic treatment guidelines.

**Recommendations**
Although routine microbiological testing is not necessary prior to commencing empirical antibiotic treatment, attempts to obtain microbiological cultures (for example, sputum cultures) should be made where feasible in stroke patients for targeted antibiotic treatment.

Antibiotic Treatment Considerations for SAP Based on Presumed Microbial Etiology
Based on the available evidence for bacterial species,\(^8\) consensus was reached that antibiotics for SAP should cover Gram positive cocci, coliforms and, when risk factors are present, *Pseudomonas* (see below). Empirical antibiotic treatment for early SAP (<72 h of stroke onset) to cover CAP pathogens was recommended and additional cover for Gram negative bacilli was agreed from ≥ 72 h and ≤ 7 d (late SAP) of stroke symptom onset. Consensus was reached that in cases of SAP where pneumonia was diagnosed in the community preceding stroke onset, then it would be reasonable to treat for CAP with antibiotics including cover for atypical organisms. The available literature for microbial etiology of aspiration pneumonia was considered.\(^{17}\) Aspiration pneumonia has previously been regarded as being predominantly due to anaerobes (e.g. *Bacteroides* spp., *Fusobacterium* spp.) but more recent studies have reported less contribution from anaerobes (<20%) with greater prevalence of *S. aureus*, Gram negative bacilli and aerobic organisms.\(^{18,19,20}\) This has been reflected by specialist societal antibiotic recommendations for aspiration pneumonia (Table 2).

**Recommendations**

1. For patients with pneumonia manifesting after admission and < 72 h of stroke onset (Early SAP) and without special circumstances (see below), empirical antibiotics to cover typical CAP pathogens i.e. Gram positive cocci in addition to *Haemophilus influenzae* and *Moraxella catarrhalis* are recommended.
2. For patients with pneumonia manifesting ≥ 72 h, but before 7 days of stroke onset (Late SAP) and without special circumstances (see below), empirical antibiotics to cover coliforms (with or without coverage of P. aeruginosa, if risk factors*) in addition to covering pathogens for CAP are recommended.

3. No additional anti-microbial coverage is required if aspiration is suspected or confirmed.

4. When SAP occurs with a diagnosis of pneumonia in the community clearly preceding stroke onset, antibiotic treatment to cover CAP including atypical organisms is recommended.

*Risk factors for P. aeruginosa: pre-existing immune suppression (e.g. HIV infection, transplant recipients, severe burns), pre-existing pulmonary disease (e.g. cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis), mechanical ventilation, prior antibiotic therapy.6

Special Circumstances

Special circumstances, including patients with pre-existing immune suppression, at risk from multidrug resistant organisms* 21 or patients admitted from other healthcare facilities or institutions were considered. In these circumstances, additional cover for Methicillin resistant S. aureus (MRSA) in addition to antibiotic coverage of other Gram negative bacteria (such as P. aeruginosa) should be used in conjunction with the above recommendations. Consensus was reached that local or societal guidelines for VAP be followed for pneumonia after 7 days of stroke onset in mechanically ventilated patients.14,15 As dysphagia is a common complication of stroke, parenteral antibiotics were suggested as initial cover for SAP if patients were placed nil orally. Early step-down to appropriate oral antibiotics should be considered once enteral feeding is secured and the patient has achieved stability. Patients who develop recurrent pneumonia in hospital following an initial antibiotic course for SAP or
HAP should be treated with antibiotics to cover HAP organisms based on liaison with local microbiology or infectious diseases expertise and policy.

**Recommendations**

1. **For stroke patients at risk for drug resistant organisms**, admitted from health care facilities or with pre-existing immune-suppression, additional antibiotic cover for MRSA, Extended Spectrum Beta Lactamase (ESBL)-producing enteric bacteria (E. coli, K. pneumoniae), P. aeruginosa or Acinetobacter species should be considered as clinically indicated and in conjunction with local patterns of antibiotic resistance and other recommendations for treatment of SAP and HAP.

2. **Pneumonia in stroke patients complicated by mechanical ventilation** should follow guidelines for SAP (pneumonia ≤ 7d of stroke onset) or VAP (>7d after stroke onset) guidelines respectively.

3. **Initial parenteral antibiotics are recommended** in dysphagic patients with SAP placed nil orally, with step-down to suitable oral antibiotics once enteral feeding or normal oral intake has been established, and clinical stability achieved.

4. **Recurrent pneumonia following an initial course of antibiotics for SAP or HAP** should be treated in line with local HAP guidance.

*At risk for drug resistant organisms: intravenous antibiotics within the preceding 90 d (and additionally if VAP: ≥ 5 d of prior hospitalization, preceding Acute Respiratory Distress Syndrome, preceding acute renal replacement, septic shock).*  

**Pneumonia Severity and Timing of Initiation of Antibiotics**

There is currently no evidence to support the routine use of prophylactic antibiotics to prevent development of SAP, either in unselected stroke populations or those considered at higher-risk placed nil orally. Furthermore, the STRoke Adverse outcome is associated WIt
NoSocomial Infections (STRAWINSKI) study did not support the use of procalcitonin-guided antibiotic initiation for pneumonia or other infections complicating stroke. The appropriate timing of initiation of antibiotics in probable or definite SAP therefore remains uncertain although immediate antibiotic treatment (and within 4 hours, or within 1h if septic shock) was considered acceptable and agreed in line with recommendations from the European Respiratory Society and National Institute of Clinical Excellence (NICE) guidelines. The group acknowledged that there were currently no published severity scores derived and validated in patients with SAP. Consensus was reached that the utility of pneumonia severity scores developed in CAP (for example CURB-65 and Pneumonia Severity Index [PSI]) requires evaluation in patients with SAP.

**Recommendations**

1. **Start antibiotic therapy as soon as possible and certainly within 4 hours (within 1h if sepsis or septic shock) in all patients with probable or definite SAP.**

2. **There are currently no validated severity scores for SAP and existing pneumonia severity scores for (e.g. CURB-65 or PSI) require evaluation in patients with SAP.**

**Which Antibiotics Should Be Used in SAP and For How Long?**

Evidence was considered regarding currently available antibiotic classes and mechanism of action, antibiotic resistance issues, and spectrum of antibiotic cover used in treatment of hospitalized CAP and HAP in existing guidelines (Table 2 and Table 3). The available evidence for using any particular class of antibiotic or individual antibiotic agent(s) in the treatment of SAP was also considered. Our systematic literature search found that there were no ongoing, completed or published trials comparing different antibiotic classes for treatment of SAP, or pneumonia complicating later stages of stroke (Figure 2 and Table IV in the
In our recent systematic review, the choice of antibiotics used to treat pneumonia complicating stroke was documented in only 4 (24%) studies and was determined by local hospital policy. Antibiotics commonly included β-lactam antibiotics (including ureidopenicillin and 2nd/3rd generation cephalosporins), with or without β-lactamase inhibitors and 2nd/3rd generation fluoroquinolones and were always initiated prior to obtaining antibiotic sensitivities.

Consensus was reached that there was insufficient evidence to recommend any particular antibiotic agent(s) or classes of antibiotic for treatment of SAP, and that evaluation of antibiotic treatment of SAP was a research priority. Penicillin plus β-lactamase inhibitors were preferred by the majority of the group for patients with SAP, aspiration pneumonia and recurrent pneumonia complicating stroke. Local patterns of antimicrobial resistance should be considered when determining appropriate empirical therapy. Consensus was also achieved for recommending that duration of antibiotic treatment should be guided by clinical response and should be for at least 7 days. It was acknowledged that the role of biomarkers to guide treatment duration was unknown and further research was needed in this regard.

**Recommendations**

1. **Choice of initial empirical antibiotics for early SAP (predominantly Gram positive cocci) may commonly include β-lactams and macrolides or respiratory fluoroquinolones.**

2. **Choice of initial empirical antibiotic therapy for late SAP should additionally cover Gram negative bacteria, with or without Pseudomonas cover, and may commonly include β-lactams (e.g. penicillin plus β-lactamase inhibitor, 3rd or 4th generation cephalosporins, monobactams), fluoroquinolones or aminoglycosides.**
3. Local patterns of antimicrobial resistance should be considered when determining appropriate empirical therapy.

4. Antibiotic treatment should be for at least 7 days and guided by clinical response, in the absence of validated biomarkers.
Discussion

SAP is a significant problem worldwide and optimizing antibiotic management when initiating treatment is of paramount importance. In England and Wales there were 21,623 episodes of SAP treated with antibiotics recorded in the last 3 years of the Sentinel Stroke National Audit Programme. As empirical antibiotic therapy is the cornerstone of the initial treatment of SAP, a standardized approach for clinicians initiating antibiotics could be a crucial component of antibiotic stewardship and improving clinical outcomes.

While there are existing specialist societal guidelines available for CAP and HAP, these do not necessarily translate directly to SAP. For example, in SAP there is a relative lack of robust microbiological data, frequent concern regarding aspiration, transient peripheral immune-suppression induced by stroke, a lack of validated severity scores or biomarkers to inform treatment decisions and no randomized trials to inform use of specific antibiotic agent(s) or classes. For the purpose of these consensus recommendations, we further divided SAP into early and late based on likely microbiological etiology and anticipated antimicrobial coverage. Pneumonia preceding stroke onset is common and when triggering stroke onset may subsequently manifest as pneumonia soon after admission to hospital. Whilst \( S.\ pneumoniae \), the most frequent pathogen in CAP worldwide, was detected infrequently in pneumonia complicating stroke in our recent systematic review, this likely reflects heterogeneity across the included studies (including bias towards sampling beyond the first 72h after stroke onset) plus absence of use of non-culture dependent methodologies e.g. detection of bacterial antigens or genome. By contrast, organisms usually implicated in HAP were identified most frequently in patients with pneumonia complicating stroke, particularly \( S.\ aureus, \ Enterobacteriaceae \) and \( P.\ aeruginosa \). Whilst data to specifically determine the timing of SAP onset relative to organisms cultured is at best sparse, our consensus on
antibiotic coverage was based on the concept that organisms in early SAP would overlap most with those that of CAP and those of late SAP would also include those of HAP.

Pneumonia complicating stroke has conventionally been regarded as aspiration pneumonia in the setting of dysphagia and oro-pharyngeal aspiration and may be labelled as “aspiration pneumonia” in the stroke literature. The microbial etiology and potential antibiotic coverage of aspiration pneumonia is therefore of interest to clinicians treating pneumonia in dysphagic stroke patients. Micro-aspiration is in fact the primary pathophysiological process in both CAP and HAP with the latter characterized by micro-aspiration of colonized organisms in the hospital environment. In recent years, the microbial etiology of hospitalized aspiration pneumonia appears to be less dominated by anaerobes, and broad-spectrum antibiotics such as fluoroquinolones or β-lactams (e.g. carbapenems or penicillins plus β-lactamase inhibitors) are typically recommended for empirical treatment rather than targeted coverage of anaerobes.

In adults hospitalized with CAP, fast antigen detection methods and real-time multibacterial and multiviral PCR platforms can increase the pathogen detection yield in sputum or endotracheal aspirate compared to conventional culture methods and could be used to better inform pathogen-directed antibiotic therapy. Despite the recognized issue of reduced sputum availability in stroke patients, prospective studies of patients with suspected SAP employing more rigorous sampling, such as fiberoptic bronchoscopes in selected patients, and multiplex PCR are needed to further characterize microbial etiology and validate empirical antibiotic recommendations. To our knowledge, viral pathogens have not been tested for in SAP or acute lower-respiratory tract syndromes complicating acute stroke, which may relate to availability of requisite molecular technology or perception that viral pneumonia does not align with the traditional paradigm of “aspiration” pneumonia in patients with stroke.
We were unable to make definitive recommendations for specific antibiotic classes (or antibiotic agents) for the treatment of SAP and could only make consensus recommendations for empirical antibiotic coverage based on limited knowledge of microbial etiology. Indeed, the wide variation in rates of antibacterial resistance in different parts of the world necessitates that local resistance patterns should be considered when determining appropriate empirical therapy. Likewise, there were insufficient data to make recommendations regarding antibiotic dose or duration of treatment. Choice of antibiotic class or agent may be important in SAP as antibiotics have varying antimicrobial coverage and pleiotropic effects independent of their bactericidal or bacteriostatic effects. Several antibiotics (e.g. macrolides, cephalosporins, fluoroquinolones) commonly used to treat SAP have protective or deleterious effects in experimental middle cerebral artery occlusion^{29,30,31,32} often via anti-inflammatory and immunomodulatory effects.

‘Our consensus statement proposes practical recommendations on antibiotic use in pneumonia complicating stroke, by experts within the PISCES group, using a modified Delphi approach. Our recommendations were not commissioned guidelines and hence should not be considered as a clinical guideline as this would not only require an adapted methodology (for example, PICO questionnaire framework and/or Levels of quality/expression of strength of recommendations) but would also need to cover other preventative and therapeutic strategies relevant to pneumonia complicating stroke, which is beyond the scope of the present work. However, this consensus provides the framework for a SAP guideline, which is in line with previous work from the PISCES group dealing with SAP.^{3,4}

Conclusion
Consensus opinion is proposed on antibiotic treatment for the spectrum of pneumonia complicating stroke. However, large-scale RCTs are required to evaluate the efficacy and cost-effectiveness of specific antibiotic regimens for SAP, preferably with standardized diagnostic algorithms, rigorous microbiological testing and validation of severity scores and candidate biomarker panels to guide treatment initiation and cessation. Such RCTs will inevitably be challenging when considering the logistics around organization of stroke services, regional and local site considerations (antibiotic costs, availability, susceptibility and resistance patterns, implementation issues) but are essential for informing evidence-based treatment for SAP and advancing our commitment to antibiotic stewardship in stroke unit care.
References


24. [https://www.strokeaudit.org/results/Clinical-audit/National-Results.aspx](https://www.strokeaudit.org/results/Clinical-audit/National-Results.aspx) Accessed 18th December 2018


**Table 1:** Summary of PISCES-2 consensus recommendation for antibiotic treatment of pneumonia complicating stroke

<table>
<thead>
<tr>
<th>Bacterial species in SAP are likely to be those in hospitalized CAP or HAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotic treatment should be initiated as soon as possible after diagnosis of probable or definite SAP, and within 4 hours (within 1h if sepsis or septic shock)</td>
</tr>
<tr>
<td>For early SAP (&lt;72h of stroke onset) antibiotic coverage of CAP organisms is recommended</td>
</tr>
<tr>
<td>For late SAP (≥72h &amp; ≤ 7 d of stroke onset) antibiotic coverage of CAP organisms plus coverage of coliforms (and <em>P. aeruginosa</em> if risk factors) is recommended</td>
</tr>
<tr>
<td>For pneumonia developing &gt; 7 days after stroke onset, HAP guidelines should be followed</td>
</tr>
<tr>
<td>No additional anti-microbial coverage is required if aspiration is suspected or confirmed</td>
</tr>
<tr>
<td>For patients at risk for drug resistant organisms, admitted from health care facilities or with pre-existing immune-suppression, additional antibiotic cover for MRSA, ESBL-producing enteric bacteria (<em>E. coli, K. pneumoniae</em>), <em>P. aeruginosa</em> or <em>Acinetobacter</em> species are recommended as clinically indicated and in conjunction with other recommendations for treatment of SAP and HAP</td>
</tr>
<tr>
<td>Choice of antibiotic should also be guided by available route, local antibiotic resistance patterns and other criteria with reference to societal guidelines</td>
</tr>
<tr>
<td>Pneumonia occurring in the community and clearly preceding stroke admission should be treated as hospitalized CAP including consideration of atypical organisms</td>
</tr>
<tr>
<td>Further research is needed to address uncertainties of microbial etiologies, choice of antibiotic classes (and agents), timing and duration of treatment and role of biomarkers in SAP treatment</td>
</tr>
</tbody>
</table>

SAP indicates stroke-associated pneumonia; CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; MRSA, methicillin-resistant *Staphylococcus aureus*; ESBL, extended spectrum beta lactamase
Table 2: Initial empirical antibiotic choice for hospitalized CAP and aspiration pneumonia (previously healthy individuals without known *S. aureus* resistance and prior to pathogen isolation and susceptibility testing)⁵,⁶

<table>
<thead>
<tr>
<th>European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases on management of hospitalized CAP in adults</th>
<th>Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of hospitalized CAP in Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inpatients, non-ICU treatment</strong></td>
<td><strong>Inpatients, non-ICU treatment</strong></td>
</tr>
<tr>
<td>aminopenicillin ± macrolide <strong>OR</strong></td>
<td>respiratory fluoroquinolone OR β-lactam plus macrolide</td>
</tr>
<tr>
<td>aminopenicillin/ β-lactamase inhibitor ± macrolide <strong>OR</strong></td>
<td><strong>Risk factors for Pseudomonas aeruginosa</strong></td>
</tr>
<tr>
<td>non-antipseudomonal cephalosporin <strong>OR</strong> Cefotaxime or Ceftriaxone ± macrolide <strong>OR</strong> Levofloxacin <strong>OR</strong> Moxifloxacin <strong>OR</strong> penicillin G ± macrolide</td>
<td>An anti-pneumococcal, antipseudomonal β-lactam (Piperacillin, Tazobactam, Cefepime,Imipenem, or Meropenem) + either Ciprofloxacin or Levofloxacin <strong>OR</strong></td>
</tr>
<tr>
<td><strong>Aspiration pneumonia</strong></td>
<td>The above β-lactam + an aminoglycoside and Azithromycin <strong>OR</strong></td>
</tr>
<tr>
<td>oral or parenteral β-lactam/ β-lactamase inhibitor <strong>OR</strong></td>
<td>The above β-lactam + an aminoglycoside and an anti-pneumococcal fluoroquinolone (for penicillin-allergic patients, substitute Aztreonam for above β-lactam)</td>
</tr>
<tr>
<td>Clindamycin <strong>OR</strong> parenteral cephalosporin + oral Metronidazole <strong>OR</strong> Moxifloxacin</td>
<td></td>
</tr>
</tbody>
</table>

CAP indicates community acquired pneumonia; ICU, intensive-care unit
### Table 3: Specialist societal guidelines for HAP/VAP $^{14,15}$

<table>
<thead>
<tr>
<th>European Respiratory Society, European Society of Intensive Care Medicine, European Society for Clinical Microbiology and Infectious Diseases, Associación Latinoamericana del Tórax on management of HAP in adults</th>
<th>Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of HAP in Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Low risk patients</strong> (without septic shock, with no other risk factors for MDR pathogens and those who are not in hospitals with a high background rate of resistant pathogens and with low risk of mortality)</td>
<td>Not at high risk of mortality and no factors increasing likelihood of MRSA</td>
</tr>
<tr>
<td>Narrow-spectrum antibiotics (ertapenem, ceftriaxone, cefotaxime, moxifloxacin or levofloxacin) in patients with suspected low risk of resistance and early-onset HAP/VAP</td>
<td>Piperacillin + Tazobactam or Cefepime OR Levofloxacin OR Imipenem/ Meropenem</td>
</tr>
<tr>
<td><strong>High risk patients</strong> (in patients with suspected early-onset HAP/VAP who are in septic shock, in patients who are in hospitals with a high background rate of resistant pathogens present in local microbiological data and in patients with other (non-classic) risk factors for MDR pathogens)</td>
<td>Not at high risk of mortality but with factors increasing likelihood of MRSA</td>
</tr>
<tr>
<td>Broad-spectrum empiric antibiotic therapy targeting <em>Pseudomonas aeruginosa</em> and extended-spectrum β-lactamase producing organisms</td>
<td>One of the following:</td>
</tr>
<tr>
<td></td>
<td>Piperacillin + Tazobactam OR Cefepime OR Levofloxacin OR Imipenem/ Meropenem OR Aztreonam</td>
</tr>
<tr>
<td></td>
<td><strong>PLUS</strong></td>
</tr>
<tr>
<td></td>
<td>Vancomycin OR Linezolid</td>
</tr>
<tr>
<td></td>
<td>High Risk of mortality or receipt of intravenous antibiotics during the prior 90 days</td>
</tr>
<tr>
<td></td>
<td>Two of the following (avoid 2 β-Lactams)</td>
</tr>
<tr>
<td></td>
<td>Piperacillin + Tazobactam OR Cefepime OR Levofloxacin OR Imipenem/ Meropenem OR Aztreonam OR Amikacin/Gentamicin/Tobramycin</td>
</tr>
<tr>
<td></td>
<td><strong>PLUS</strong></td>
</tr>
<tr>
<td></td>
<td>Vancomycin OR Linezolid</td>
</tr>
</tbody>
</table>

HAP indicates hospital acquired pneumonia; VAP, ventilator associated pneumonia; MDR, multiple-drug resistant; MRSA, methicillin resistant *Staphylococcus aureus*
Figure 1: Flow chart summarizing approach to antibiotic treatment of pneumonia complicating stroke (SAP indicates stroke-associated pneumonia; HAP, hospital-acquired pneumonia; CAP, community-acquired pneumonia)

Decision on parenteral antibiotics should be made in conjunction with clinical decision on severity of pneumonia with step down to oral antibiotics guided by clinical response

Initial parenteral antibiotics are recommended if patients are dysphagic and placed nil orally, with step down to oral antibiotics once enteral feeding is established and stability achieved

Pneumonia >7d after stroke in mechanically ventilated patients should be treated in line with local or regional VAP guidelines
Figure 2: Flow diagram of systematic search methodology

Records identified through database searching (N)
- MEDLINE: 321
- EMBASE: 667
- Cochrane Library: 12

References; Citations; PISCES collaboration
- N=2

Records after duplicates removed (N=706)

Records screened N=163

Eligibility criteria
- a) Age ≥ 18 years
- b) Participants with ischemic stroke, intracerebral hemorrhage, or both
- c) Fully published/completed prospective or retrospective observational studies, quasi-experimental or randomized trials
- d) Frequency of pneumonia complicating acute stroke identified
- e) Antibiotic used to treat pneumonia complicating stroke identified and treatment outcomes measured

Records excluded N=138
- Animal studies=2
- Non-stroke studies=136

Full-text articles/abstracts assessed for eligibility N=10

Full-text articles/abstracts excluded with reasons N=10
- Survey 1: Prophylactic antibiotic treatment studies
- Systematic review of prophylactic antibiotic treatment to prevent pneumonia complicating stroke

Studies included for qualitative analysis N=0
SUPPLEMENTAL MATERIAL

Antibiotic Treatment for Pneumonia Complicating Stroke: Recommendations From
The Pneumonia in Stroke Consensus (PISCES) Group

Amit K Kishore¹,² MRCP, Adam R Jeans³ MD, Javier Garau⁴ PhD, Alejandro Bustamante⁵
PhD, Lalit Kalra⁶ PhD, Peter Langhorne⁷ PhD, Angel Chamorro⁸ PhD, Xabier Urra⁹ PhD,
Mira Katan¹⁰ MD MSc, Mario Di Napoli¹⁰ MD, Willeke Westendorp¹¹ MD, Paul J
Nederkoorn¹¹ PhD, Diederik van de Beek¹¹ PhD, Christine Roffe¹² MD, Mark Woodhead¹³
DM, Joan Montaner⁵,¹⁴ PhD, Andreas Meisel¹⁵ MD, Craig J Smith¹,² MD

¹Greater Manchester Comprehensive Stroke Centre, Manchester Academic Health Science
Centre, Salford Royal Foundation Trust, UK; ²Division of Cardiovascular Sciences,
University of Manchester, Manchester, UK; ³Centre for Biostatistics, University of
Manchester, Salford Royal Foundation Trust, UK; ⁴Department of Medicine, Hospital
Universitari Mutua de Terrassa, Barcelona, Clinica Rotger Quirosexual, Palma of Mallorca,
Spain; ⁵Neurovascular Research Lab, Vall d'Hebron Research Institute, Barcelona, Spain,
Spain; ⁶Clinical Neurosciences, King's College Hospital NHS Foundation Trust London, UK;
⁷Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK;
⁸Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic, University of
Barcelona, Barcelona, Spain; ⁹Department of Neurology, Stroke Center, University Hospital
of Zurich, Zurich, Switzerland; ¹⁰Stroke Unit, San Camillo de` Lellis General Hospital, Rieti,
Italy; ¹¹Amsterdam UMC, University of Amsterdam, Department of Neurology, Amsterdam
Neuroscience, Meibergdreef, Amsterdam, Netherlands; ¹²Keele University Institute for
Science and Technology in Medicine, Guy Hilton Research Centre, Stoke-on-Trent, UK; ¹³
Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic
Health Science Centre, Manchester, UK; ¹⁴Institute de Biomedicine of Seville,
IBiS/Hospitales Universitarios Virgen del Rocio y Macarena, University of Seville, Seville,
Spain; ¹⁵NeuroCure Clinical Research Center, Center for Stroke Research Berlin, Department
of Neurology, Charité Universitätsmedizin Berlin, Germany

Cover title: Antibiotic treatment for pneumonia complicating stroke
Online Only Table I: Search terms

<table>
<thead>
<tr>
<th>Search terms</th>
<th>Publication Year</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subject Search in MESH:</strong> exp *Cerebrovascular disorders/; exp <em>Pneumonia/; exp</em>antibiotic agent</td>
<td>1946-2018</td>
</tr>
<tr>
<td><strong>Subject Search on EMTREE:</strong> exp *Cerebrovascular disease/ exp *Pneumonia/; * exp antiinfective agent</td>
<td>1901-2018</td>
</tr>
<tr>
<td>All text: “stroke” , “pneumonia” , “antibiotic treatment”</td>
<td>1901-2018</td>
</tr>
</tbody>
</table>

Publication Year from 1980 to 2018, in Cochrane Reviews (Protocols only), Trials and Methods Studies (Word variations have been searched)
Online Only Table II: Eligibility criteria

**Inclusion criteria**

- Age $\geq$ 18 years
- Fully published studies or abstracts
- English or non-English language
- Inpatients with ischemic stroke, intracerebral haemorrhage, or both
- Randomized and other controlled trials, including cluster RCTs, controlled (non-randomized) clinical trials (CCTs) or cluster trials, prospective comparative cohort studies, retrospective observational studies, case-control or nested case-control studies.
- Incidence or prevalence of pneumonia following admission with stroke reported
- Antibiotics used to treat pneumonia complicating stroke identified and treatment outcomes measured

**Exclusion criteria**

- Age $<$ 18 years
- Exclusively intubated and mechanically ventilated patients
- Exclusively pneumonia preceding index stroke
- Case reports
**Online Only Table III: Summary of consensus statements and process**

<table>
<thead>
<tr>
<th></th>
<th>Preliminary Consensus (%)</th>
<th>Final Consensus (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Is there a clinical need for an antibiotic treatment guideline specifically for pneumonia complicating stroke?</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>No</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>If yes, the antibiotic treatment guideline for pneumonia complicating stroke should be applied to which of the following?</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonia occurring as an inpatient at any time point after stroke</td>
<td>27</td>
<td>0</td>
</tr>
<tr>
<td>Pneumonia within 7 days after admission with stroke (Stroke associated pneumonia, SAP)</td>
<td>87</td>
<td>100</td>
</tr>
<tr>
<td>Pneumonia in patients with known or strongly suspected of aspiration (e.g. witnessed vomiting, nil-by-mouth)</td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>Recurrent pneumonia during admission (e.g. in tube fed patients)</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Patients developing pneumonia while mechanically ventilated</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td><strong>Do you think the bacterial etiology of pneumonia complicating stroke has some overlap with (can choose more than 1):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital acquired pneumonia (HAP)</td>
<td>87</td>
<td>75</td>
</tr>
<tr>
<td>Community acquired pneumonia (CAP)</td>
<td>67</td>
<td>75</td>
</tr>
<tr>
<td>Ventilator-associated pneumonia (VAP)</td>
<td>53</td>
<td>0</td>
</tr>
<tr>
<td>None of the above</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Should empirical treatment of pneumonia complicating stroke cover (can choose more than one):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gram positive cocci (e.g. <em>Staphylococcus aureus</em>, <em>Streptococcus pneumoniae</em> etc)?</td>
<td>73</td>
<td>75</td>
</tr>
<tr>
<td>Coliforms (e.g. <em>Escherichia coli</em>, <em>Klebsiella spp</em>)?</td>
<td>60</td>
<td>75</td>
</tr>
<tr>
<td>Pseudomonas species</td>
<td>7</td>
<td>75</td>
</tr>
<tr>
<td>None of the above</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>All of the above</td>
<td>34</td>
<td>100</td>
</tr>
<tr>
<td>Other</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td><strong>Is there sufficient evidence to currently justify empirical recommendation of one particular antibiotic class (or dual therapy) over another for (can choose more than one):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonia complicating stroke at any time after admission?</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>Stroke associated pneumonia</td>
<td>27</td>
<td>0</td>
</tr>
<tr>
<td>Pneumonia in patients with known or strongly suspected aspiration (e.g. witnessed vomiting, nil-by-mouth secondary to dysphagia)?</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>Recurrent pneumonia during admission after stroke?</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>None of the above</td>
<td>67</td>
<td>100</td>
</tr>
<tr>
<td><strong>Is a randomized trial comparing different empirical antibiotics for suspected or confirmed SAP justified?</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>80</td>
<td>100</td>
</tr>
<tr>
<td>No</td>
<td>20</td>
<td>0</td>
</tr>
</tbody>
</table>
**Online only Table IV:** Excluded studies from systematic literature search


